MYELOFIBROSIS，MF
Clinical trials for MYELOFIBROSIS，MF explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS，MF trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS，MF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Which drug wins for myelofibrosis? new trial pits momelotinib against ruxolitinib
Disease control Not yet recruitingThis study tests two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug works better at shrinking an enlarged spleen and reducing the need for blood transfusions. About 268 particip…
Matched conditions: MYELOFIBROSIS，MF
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 09:25 UTC
-
New drug aims to stop post-transplant anemia in high-risk blood cancer patients
Disease control Not yet recruitingThis study tests whether the drug luspatercept can prevent severe anemia (low red blood cells) after a stem cell transplant in people with blood cancers who also have moderate to severe myelofibrosis (scarring in the bone marrow). About 196 adults aged 18-65 will be randomly assi…
Matched conditions: MYELOFIBROSIS，MF
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 26, 2026 09:23 UTC
-
New drug ZE74-0282 targets rare blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests an experimental drug, ZE74-0282, in about 60 adults with polycythemia vera or myelofibrosis caused by a JAK2 V617F mutation. The main goals are to find the safest dose and see if the drug shows signs of fighting the disease. Participants will take the…
Matched conditions: MYELOFIBROSIS，MF
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
Can blood cancer patients safely stop anti-rejection drugs sooner?
Disease control Not yet recruitingThis study tests whether patients who receive a stem cell transplant for blood cancers can safely stop the anti-rejection drug tacrolimus earlier than usual. The goal is to reduce side effects while still preventing graft-versus-host disease (GVHD). About 50 participants will be …
Matched conditions: MYELOFIBROSIS，MF
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug combo may boost stem cell success in rare bone marrow cancer
Disease control Not yet recruitingThis study tests whether the drug gecacitinib, given before, during, and after a stem cell transplant, can help people with myelofibrosis (a rare bone marrow cancer) live longer without serious complications like graft-versus-host disease or relapse. About 39 adults aged 18-75 wi…
Matched conditions: MYELOFIBROSIS，MF
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New study tracks Real-World impact of momelotinib on enlarged spleens in myelofibrosis
Disease control Not yet recruitingThis study will observe 93 adults with myelofibrosis who are starting momelotinib as part of their normal care. Researchers want to see how well the drug reduces an enlarged spleen after 6 months. The goal is to understand the drug's real-world effectiveness beyond clinical trial…
Matched conditions: MYELOFIBROSIS，MF
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated May 14, 2026 12:04 UTC